Sirnaomics’ Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma

GAITHERSBURG, Md., Dec. 6, 2017 /PRNewswire/ — Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Office of Orphan Product Development division of the FDA has granted Orphan-drug…